Zacks Research Has Negative Outlook for A Q2 Earnings

Agilent Technologies, Inc. (NYSE:A) – Zacks Research reduced their Q2 2025 earnings estimates for Agilent Technologies in a note issued to investors on Wednesday, March 19th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $1.26 per share for the quarter, down from their prior forecast of $1.33. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.57 per share. Zacks Research also issued estimates for Agilent Technologies’ Q4 2025 earnings at $1.58 EPS, Q3 2026 earnings at $1.53 EPS, Q4 2026 earnings at $1.65 EPS, FY2026 earnings at $6.03 EPS, Q1 2027 earnings at $1.61 EPS and FY2027 earnings at $6.61 EPS.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The business had revenue of $1.68 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%.

A number of other analysts have also recently weighed in on A. JPMorgan Chase & Co. lowered their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 26th. StockNews.com raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 24th. Sanford C. Bernstein decreased their price objective on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a research note on Tuesday, November 26th. Robert W. Baird decreased their price objective on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. Finally, Bank of America decreased their price objective on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Seven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $146.15.

Agilent Technologies Stock Performance

NYSE A opened at $120.72 on Friday. The stock has a market cap of $34.42 billion, a P/E ratio of 27.75, a PEG ratio of 3.38 and a beta of 1.11. The company’s 50-day simple moving average is $136.74 and its 200 day simple moving average is $137.29. Agilent Technologies has a twelve month low of $117.17 and a twelve month high of $155.35. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56.

Institutional Investors Weigh In On Agilent Technologies

Several large investors have recently bought and sold shares of the company. CKW Financial Group increased its position in shares of Agilent Technologies by 114.9% during the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock worth $25,000 after acquiring an additional 100 shares in the last quarter. Global X Japan Co. Ltd. grew its position in Agilent Technologies by 161.1% in the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 116 shares in the last quarter. Redwood Park Advisors LLC bought a new position in Agilent Technologies in the fourth quarter valued at $27,000. Lee Danner & Bass Inc. bought a new position in Agilent Technologies in the fourth quarter valued at $29,000. Finally, Sunbelt Securities Inc. grew its position in Agilent Technologies by 640.0% in the fourth quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 192 shares in the last quarter.

Insider Activity at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the transaction, the chief executive officer now directly owns 39,652 shares in the company, valued at $5,947,800. This represents a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $121.98, for a total transaction of $232,737.84. Following the completion of the sale, the vice president now directly owns 21,786 shares of the company’s stock, valued at $2,657,456.28. The trade was a 8.05 % decrease in their position. The disclosure for this sale can be found here.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be issued a $0.248 dividend. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 annualized dividend and a yield of 0.82%. Agilent Technologies’s dividend payout ratio is currently 22.76%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.